

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: **Diprivan® (propofol) Injectable Emulsion, USP**
Synonyms: Propofol
Manufacturer Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Customer Service Phone Number: (888) 386-1300
Health Issues Information: (800) 551-7176
SDS Creation Date: January 08, 2009
SDS Revision Date: February 19, 2024

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word: DANGER.

GHS Class: Respiratory sensitisation, category 1.
 Skin Sensitization, category 1.
 Reproductive toxicity, Effects on or via lactation.

Hazard Statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
 May cause an allergic skin reaction.
 May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use.
 Do not breathe dust/fume/gas/mist/vapours/spray.
 Avoid breathing dust/fume/gas/mist/vapours/spray.
 Avoid contact during pregnancy and while nursing.
 Wash hands thoroughly after handling.
 Do not eat, drink or smoke when using this product.
 Contaminated work clothing should not be allowed out of the workplace.
 Wear protective gloves/protective clothing/eye protection/face protection.
 In case of inadequate ventilation wear respiratory protection.
 IF ON SKIN: Wash with plenty of water.
 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
 IF exposed or concerned: Get medical advice/attention.
 Specific treatment (see ... on this label).
 If skin irritation or rash occurs: Get medical advice/attention.
 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.
 Take off contaminated clothing and wash it before reuse.
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye: Contact with eyes may cause irritation.

Signs/Symptoms: Possible adverse reactions include: bradycardia, arrhythmia, hypotension, hypertension, apnea, rash, and pruritus. Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions: Individuals with a known hypersensitivity to Diprivan Injectable Emulsion or its components.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Propofol	2078-54-8	1 %	
Glycerol	56-81-5	22.5 mg/mL	
Egg Lecithin	93685-90-6	12 mg/mL	
Disodium EDTA Dihydrate	139-33-3	0.005 %	
Soybean Oil	8001-22-7	100 mg/mL	

SECTION 4 : FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store between 4 to 22°C (40 to 72°F). Do not freeze.
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/npptl/topics/respirators/>) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

Glycerol:

Guideline OSHA: PEL-TWA: 5 mg/m3 Respirable fraction (R)

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution.
Color: White
Boiling Point: 242°C (468°F)
Melting Point: Not established.
Solubility: Very slightly soluble. in water.
Vapor Density: Not established.
Vapor Pressure: Not established.
Percent Volatile: Not established.
pH: 7.0 - 8.5
Molecular Formula: Mixture
Molecular Weight: 178.27
Flash Point: Not established.
Flash Point Method: Not established.
Auto Ignition Temperature: Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.
Hazardous Polymerization: Not reported.
Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

SECTION 11 : TOXICOLOGICAL INFORMATION

Teratogenicity: Pregnancy Category B: No adequate and well-controlled studies in pregnant women are available. However, reproductive studies have been performed in rats and rabbits at intravenous doses of 15 mg/kg and have revealed no evidence of impaired fertility or harm to the fetus due to propofol.

Propofol:

RTECS Number: SL0810000

Skin: Acute Toxicity:
Single lethal dose, Dermal Rat: 0.5 mL/kg

Ingestion: Oral - Rat LD50: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: 1100 mg/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information :

Intravenous. - Rat LD50: 42 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intravenous. - Mouse LD50: 50 mg/kg [Behavioral - general anesthetic Behavioral - altered sleep time (including change in righting reflex) Behavioral - analgesia]
 Intravenous. - Rabbit LDLo: 20 mg/kg [Behavioral - general anesthetic Behavioral - sleep Behavioral - muscle weakness]
 Intravenous. - Rat TDLo: 70 mg/kg/1H [Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)]
 Intravenous. - Rat TDLo: 13.5 mg/kg [Vascular - BP lowering not characterized in autonomic section Vascular - regional or general arteriolar or venous dilation]
 Intravenous. - Rat TDLo: 21.7 mg/kg [Cardiac - change in rate]
 Intravenous. - Human TDLo: 3 mg/kg [Behavioral - general anesthetic]
 Intravenous. - Rat TDLo: 4 mg/kg [Brain and Coverings - recordings from specific areas of CNS]
 Intravenous. - Mouse TDLo: 10 mg/kg [Brain and Coverings - other degenerative changes]
 Intravenous. - Human TDLo: 5.4 mg/kg [Peripheral Nerve and Sensation - local anesthetic Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression]
 Intravenous. - Human TDLo: 5.4 mg/kg [Gastrointestinal - nausea or vomiting]
 Intravenous. - Human TDLo: 4 mg/kg/40M [Vascular - measurement of regional blood flow Biochemical - Metabolism (Intermediary) - other]
 Intravenous. - Rat TDLo: 4 mg/kg/20M [Brain and Coverings - other degenerative changes]
 Intravenous. - Rabbit TDLo: 84 mg/kg [Lungs, Thorax, or Respiration - other changes Blood - changes in leukocyte (WBC) count Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation]
 Intravenous. - Human TDLo: 0.64 mg/kg [Behavioral - convulsions or effect on seizure threshold Gastrointestinal - changes in structure or function of salivary glands Kidney/Ureter/Bladder - incontinence]
 Intravenous. - Rat TDLo: 60 mg/kg [Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation]
 Intravenous. - Human TDLo: 0.8 ug/kg/30S [Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - respiratory depression Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)]
 Intraperitoneal. - Mouse LD50: 170 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intraperitoneal. - Mouse TDLo: 51.3 mg/kg [Behavioral - anticonvulsant]
 Intraperitoneal. - Mouse TDLo: 100 mg/kg [Brain and Coverings - other degenerative changes Behavioral - alteration of classical conditioning Biochemical - Metabolism (Intermediary) - other]
 Intraperitoneal. - Mouse TDLo: 12.5 mg/kg [Behavioral - analgesia]
 Intraperitoneal. - Rat TDLo: 40 mg/kg [Peripheral Nerve and Sensation - sensory change involving peripheral nerve]
 Intraperitoneal. - Rat TDLo: 280 mg/kg/14D (intermittent) [Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Liver - other changes]

Glycerol :

RTECS Number: MA805000

Eye: Eye - Rabbit Standard Draize test.: 500 mg/24H

Skin: Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than lethal dose value]
 Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H

Inhalation: Inhalation - Rat LC50: >570 mg/m³/1H [Details of toxic effects not reported other than lethal dose value]

Ingestion: Oral - Rat LD50: 12600 mg/kg [Behavioral - General anesthetic Behavioral - Muscle weakness Liver - Other changes]
 Oral - Mouse LD50: 4090 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Oral - Rat LD50: 12600 mg/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information : Intravenous. - Rat LD50: 5566 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intravenous. - Mouse LD50: 4250 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intravenous. - Rabbit LD50: 53 gm/kg [Details of toxic effects not reported other than lethal dose value]
 Subcutaneous - Rat LD50: 100 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Subcutaneous - Mouse LD50: 91 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intraperitoneal. - Rat LD50: 4420 mg/kg [Behavioral - toxic psychosis Cardiac - other changes Kidney/Ureter/Bladder - other changes]
 Intraperitoneal. - Mouse LD50: 8700 mg/kg [Behavioral - altered sleep time (including change in righting reflex)]

Disodium EDTA Dihydrate :

RTECS Number: AH4375000

Eye: Rabbit, not irritating.

Skin: Rabbit, not irritating.

Inhalation: Inhalation - Rat LOAEC 30 mg/m³/6 h (aerosol) (OECD Guideline 412) (ECHA)

Ingestion: Oral - Rat LD50 2800 mg/kg (ECHA)

Other Toxicological Information : Intravenous. - Mouse LD50 : 56 mg/kg (RTEC)

Soybean Oil :

RTECS Number: WG4862000

Other Toxicological Information : Intravenous. - Rat LD50: 16500 mg/kg [Details of toxic effects not reported other than lethal dose value]
 Intravenous. - Mouse LD50: 22100 mg/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

Disodium EDTA Dihydrate :

Ecotoxicity: Guppy (Poecilia reticulata) LC50 (96hr) 320 mg/L (OECD SIDS)
Zebra fish (Danio rerio) NOEC (35d) >= 25.7 mg/L (OECD Guideline 210 , GLP) (TS : Ethylenediaminetetraacetic acid, calcium disodium complex)
Water flea (Daphnia magna) EC50 (48hr) 140 mg/L, NOEC (21d) 25 mg/L (EEC Guideline XI/681/86, GLP) (TS : Ethylenediaminetetraacetic acid, disodium salt)
Green algae (Scenedesmus quadricauda) NOEC (24 d) 200 mg/L (ECHA)

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated.
DOT UN Number: Not Regulated.
IATA Shipping Name: Non regulated.
IATA UN Number: Non regulated.
IMDG UN Number : Non regulated.
IMDG Shipping Name : Non regulated.

SECTION 15 : REGULATORY INFORMATION

Propofol :

TSCA Inventory Status: Listed
EINECS Number: 218-206-6
Canada DSL: Listed

Glycerol :

TSCA Inventory Status: Listed
EINECS Number: 200-289-5
Canada DSL: Listed

Egg Lecithin :

EINECS Number: 297-639-2
Canada DSL: Listed

Disodium EDTA Dihydrate :

TSCA Inventory Status: Listed
EINECS Number: 205-358-3
Canada DSL: Listed

Soybean Oil :

TSCA Inventory Status: Listed
EINECS Number: 232-274-4
Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 2
HMIS Fire Hazard: 0
HMIS Reactivity: 0
HMIS Personal Protection: X

SDS Creation Date: January 08, 2009

SDS Revision Date: February 19, 2024

SDS Revision Notes: Overall SDS review - no changes to formulation. Added synonym to product name. Revised the HMIS ratings for Health, Flammability, Reactivity, and Personal Protective Equipment (PPE).

Disclaimer: The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

